Alan Liddle

Alan has over 35 years of experience in developing and commercialising medical and biological therapeutics.

Alan's research & executive management experience in the medical and the biotechnology research sector encompasses immunology and bio-therapeutics for cancer and autoimmune diseases, cardiology and microbiome health.

Currently, Alan is Chairman and CEO of Sangui Bio, a company he co-founded in 2015. Sangui is commercialising its discoveries in the role of red blood cells in immune system activation and regulation and associated biomarkers.

Alan co-founded and was CEO & Director of Immune System Therapeutics Ltd from 2001 to 2011. He was also the Founder, CEO & Director of MicroMedical Industries Limited from 1986 to 1998. He built the company from a start-up to an ASX listed, international provider of medical monitoring and diagnostic products and a developer of artificial heart technologies.

From 1983 to 1985, Alan held the following positions: Manager Corporate Development & Investment with the investment bank Edward Lumley Limited, a member of the Board of Lumley Underwriting Limited and Company Secretary Lumley Financial Services Ltd. Prior to his biomedical career, Alan was a neuropsychologist researcher at the University of Sydney specialising in rehabilitation of patients following traumatic brain injuries. He was the co-inventor of the rehabilitation software program: Dynamind3D.

Alan co-founded and was a Director of MothersBabies Ltd (2018 to 2021) – a charitable organisation that is funding educational initiatives, research and clinical trials pertaining to microbiome health in pregnancy and women’s health. He is also a director of Ausimed Ltd a charity that supports medical research initiatives. He holds a BA (Hons) from the University of Sydney and MBA from the University of NSW and is a fellow of the Australian Institute of Company Directors. Alan resides in Sydney.